DNA
Ginkgo Bioworks Holdings, Inc.
NYSE · Healthcare · Biotechnology · US
$10.07
−1.95%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$10.38
From 52W high−32.78%
Volume2.31M
Market cap$678.12M
P/E (TTM)—
P/S (TTM)6.1x
Div yield—
Key dataOct 19, 2026
Open
$10.38
From 52W high
−32.78%
Volume
2.31M
Market cap
$678.12M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.2x
P/E (TTM)
—
RSI (14)
48.1
MomentumView details →
1D Return
−1.95%
YTD Return
+23.24%
SummaryUpdated Jun 1, 2026
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) is a biotechnology platform company founded in 2008 and headquartered in Boston, Massachusetts. The company went public in April 2021 through a SPAC merger. Ginkgo operates as a "platform for cell programming," essentially functioning as a biotechnology foundry that engineers microorganisms to produce various products for customers across multiple industries. The company has evolved from a pure-play cell engineering service provider to a diversified biotechnology platform offering cell programming services, biosecurity solutions, and laboratory automation tools.
Similar companies
Latest newsMore news →
Switch Bioworks entered a strategic collaboration with Bayer CropScience AG to combine Switch’s microbial strains with Bayer’s crop hybrids and advance switchable biofertilizer technology.7d agoGinkgo Bioworks Holdings, Inc. is providing remote laboratory access through the The National Science Foundation's Ginkgo Bioworks Holdings, Inc. program and integrating high-speed cellular imaging tools into its Boston facility.10d agoGinkgo Bioworks Holdings, Inc. announced that it will provide researchers in the The National Science Foundation’s X-Labs program with in-kind access to its autonomous Boston laboratory, including cloud lab time and protein testing services.11d ago